Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $50.56, for a total value of $151,680.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Joseph Klein III also recently made the following trade(s):

  • On Saturday, December 29th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $50.56, for a total value of $151,680.00.
  • On Friday, December 15th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $51.69, for a total value of $155,070.00.
  • On Thursday, November 30th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $53.55, for a total value of $160,650.00.
  • On Wednesday, November 15th, Joseph Klein III sold 2,250 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $53.56, for a total value of $120,510.00.
  • On Monday, November 13th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $55.39, for a total value of $166,170.00.

Shares of Ionis Pharmaceuticals Inc (NASDAQ IONS) opened at $49.48 on Friday. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals Inc has a 52-week low of $37.26 and a 52-week high of $65.51. The company has a market capitalization of $6,242.27, a P/E ratio of 329.89 and a beta of 2.86.

Several equities analysts have recently weighed in on IONS shares. BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. BMO Capital Markets reissued an “outperform” rating and set a $69.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Barclays reduced their price target on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a research report on Thursday, September 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $50.31.

Hedge funds have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at $100,000. Parallel Advisors LLC lifted its holdings in Ionis Pharmaceuticals by 60.3% during the third quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock worth $182,000 after acquiring an additional 1,250 shares in the last quarter. Hanseatic Management Services Inc. lifted its holdings in Ionis Pharmaceuticals by 1.2% during the second quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after acquiring an additional 41 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares in the last quarter. Finally, WFG Advisors LP lifted its holdings in shares of Ionis Pharmaceuticals by 77.2% in the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after purchasing an additional 1,655 shares in the last quarter. 91.40% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Ionis Pharmaceuticals Inc (IONS) Director Sells $151,680.00 in Stock” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/01/05/ionis-pharmaceuticals-inc-ions-director-sells-151680-00-in-stock.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.